As of March 2000, all U.S. children had access to hepatitis B vaccines that do not contain thimerosal as a preservative. Research on the potential health effects of exposure to thimerosal is continuing, and findings will be monitored closely by PHS to determine whether any changes in policy are needed. AAFP, AAP, and PHS, in consultation with the ACIP, reaffirm the goal set in July 1999 to remove or greatly reduce thimerosal from vaccines as soon as possible. On the basis of information from the Food and Drug Administration and manufacturers, PHS projects that the United States will complete its transition to a secure routine pediatric vaccine supply free of thimerosal as a preservative by the first quarter of 2001. The vaccination of children in much of the world will continue to require the use of multidose vials because of cost, production, and storage capacity.
Multidose vials require a preservative to prevent microbial contamination after the vial is opened.
For multidose vials, manufacturers are encouraged to seek alternatives to thimerosal. The Immunization Services Division is requesting assistance in filling the position. It will remain open until August 15, 2000. The Epidemiology and Surveillance Division conducts epidemiologic research and surveillance regarding vaccines and vaccine-preventable diseases, and is responsible for policy development and technical consultation in this area. The Director also serves as NIP's lead representative for the Advisory Committee on Immunization Practices.